EUHASS is a pharmacovigilance program to monitor the safety of treatments for people with inherited bleeding disorders in Europe. Haemophilia treatment centres report adverse events directly to the EUHASS website and regular surveillance reports are produced.
The program’s aims are as follows:
- To monitor the safety of treatments for people with haemophilia and other inherited bleeding disorders in Europe.
- To inform clinicians, regulators and other interested parties of the treatment patterns and adverse events reported for these patients in Europe.
- To set up a publicly available database of all the Haemophilia centres in Europe with details of how they can be accessed by patients, and information on relevant patient, doctor, nurse and physiotherapist organisations in each country.
- To set up a publicly available directory containing information and publications lists for all the clotting factor products used in Europe to treat haemophilia and other inherited bleeding disorders.
For more information, visit the EUHASS website.